Boswellia Serrata - Promacta (Eltrombopag) Interaction

Interaction Details

Pharmacist Analysis

No interaction has been noted between Boswellia and the drug in question on this interaction check.

In terms of other interactions, Boswellia serrata has been shown in laboratory studies to mildly inhibit several enzymes involved in drug metabolism, including CYP1A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4. This inhibition may increase the levels of drugs metabolized by these enzymes, potentially leading to adverse effects.

However, it is important to note that this inhibition has only been seen in a lab setting, and has not been reported in humans. Whether or not Boswellia supplements have clinically significant drug interactions due to the effects on the above enzymes isn't well known. In most cases, it appears unlikely that these interactions would be clinically significant as there is a lack of reports of problems being caused in humans.

In addition, Boswellia serrata may interact with immunosuppressive drugs. 

Studies show that Boswellia may help reduce the activity of some cells involved in autoimmune diseases. This could lead to a decrease in the production of antibodies and certain immune cells. However, other studies have found that certain components of Boswellia serrata may actually stimulate the immune system in certain situations. More research is needed to better understand the effect of Boswellia on immunosuppressive drugs.

Eltrombopag Overview

• Eltrombopag is used to increase the number of platelets (cells that help the blood clot) to decrease the risk of bleeding in adults and children 1 year of age and older who have chronic immune thrombocytopenia (ITP; an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood) and who have not been helped or cannot be treated with other treatments, including medications or surgery to remove the spleen. Eltrombopag is also used to increase the number of platelets in people who have hepatitis C (a viral infection that may damage the liver) so that they can begin and continue treatment with interferon (Peginterferon, Pegintron, others) and ribavirin (Rebetol). Eltrombopag is also used in combination with other medications to treat aplastic anemia (condition in which the body does not make enough new blood cells) in adults and children 2 years of age and older. It is also used to treat aplastic anemia in adults who have not been helped with other medications. Eltrombopag is used to increase the number of platelets enough to decrease the risk of bleeding in people with ITP or aplastic anemia, or to allow treatment with interferon and ribavirin in people with hepatitis C. However it is not used to increase the number of platelets to a normal level. Eltrombopag should not be used to treat people who have low numbers of platelets due to conditions other than ITP, hepatitis C, or aplastic anemia. Eltrombopag is in a class of medications called thrombopoietin receptor agonists. It works by causing the cells in the bone marrow to produce more platelets.

Boswellia Serrata - More Interactions

Boswellia Serrata interacts with 920 drugs

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.